145 related articles for article (PubMed ID: 33506273)
1. Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice.
Escudero-Vilaplana V; Collado-Borrell R; Del Monte-Millán M; Hoyo-Muñoz A; Gómez Martínez-Sagrera P; Revuelta-Herrero JL; Marzal-Alfaro B; Gonzalez-Haba E; López-Tarruella Cobo S; Jerez Gilarranz Y; Herranz A; Sanjurjo M; Martin M
Support Care Cancer; 2021 Aug; 29(8):4673-4681. PubMed ID: 33506273
[TBL] [Abstract][Full Text] [Related]
2. Oral antineoplastic agents: assessment of safety and dose adjustments in clinical practice.
Escudero-Vilaplana V; Revuelta-Herrero JL; Collado-Borrell R; Marzal-Alfaro B; Gimenez-Manzorro A; Herranz-Alonso A; Sanjurjo-Saez M
Expert Opin Drug Saf; 2019 Sep; 18(9):861-868. PubMed ID: 31282227
[No Abstract] [Full Text] [Related]
3. Photo elicitation, an approach to better understanding the patient experience with OAAs: pilot study and future implications.
Manojlovich M; Blok A; Wright N; Azhari E; Farris KB; Friese CR; Mackler E; Titler M; Byrnes M
Support Care Cancer; 2023 Oct; 31(12):652. PubMed ID: 37878093
[TBL] [Abstract][Full Text] [Related]
4. Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis.
Elting LS; Chang YC; Parelkar P; Boers-Doets CB; Michelet M; Hita G; Rouleau T; Cooksley C; Halm J; Vithala M; Bossi P; Escalante C; Brennan MT;
Support Care Cancer; 2013 Nov; 21(11):3243-54. PubMed ID: 23636648
[TBL] [Abstract][Full Text] [Related]
5. Potential drug interactions between targeted oral antineoplastic agents and concomitant medication in clinical practice.
Escudero-Vilaplana V; Collado-Borrell R; Hoyo-Muñoz A; Gimenez-Manzorro A; Calles A; Osorio S; Herranz-Alonso A; Sanjurjo-Sáez M
Expert Opin Drug Saf; 2020 Aug; 19(8):1041-1048. PubMed ID: 32529857
[TBL] [Abstract][Full Text] [Related]
6. Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.
Swain SM; Schneeweiss A; Gianni L; Gao JJ; Stein A; Waldron-Lynch M; Heeson S; Beattie MS; Yoo B; Cortes J; Baselga J
Ann Oncol; 2017 Apr; 28(4):761-768. PubMed ID: 28057664
[TBL] [Abstract][Full Text] [Related]
7. Potentially Hazardous Drug-Drug Interactions Associated With Oral Antineoplastic Agents Prescribed in Chinese Tertiary Care Teaching Hospital Settings: A Multicenter Cross-Sectional Study.
Wang H; Shi H; Wang Y; Wang N; Li Y; Yang Q; Li Y; Liu C; Zan Y; Feng S; Xie J
Front Pharmacol; 2022; 13():808848. PubMed ID: 35177990
[No Abstract] [Full Text] [Related]
8. Prevalence of the coprescription of clinically important interacting drug combinations involving oral anticancer agents in Singapore: a retrospective database study.
Ko Y; Tan SL; Chan A; Wong YP; Yong WP; Ng RC; Lim SW; Salim A
Clin Ther; 2012 Aug; 34(8):1696-704. PubMed ID: 22795926
[TBL] [Abstract][Full Text] [Related]
9. Endoscopy in patients with diarrhea during treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors: Is the cause in the mucosa?
Boers-Sonderen MJ; Mulder SF; Nagtegaal ID; Derikx LA; Wanten GJ; Mulders PF; van der Graaf WT; Hoentjen F; van Herpen CM
Acta Oncol; 2016; 55(4):444-8. PubMed ID: 26959411
[TBL] [Abstract][Full Text] [Related]
10. Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis.
Martel S; Bruzzone M; Ceppi M; Maurer C; Ponde NF; Ferreira AR; Viglietti G; Del Mastro L; Prady C; de Azambuja E; Lambertini M
Cancer Treat Rev; 2018 Jan; 62():123-132. PubMed ID: 29108713
[TBL] [Abstract][Full Text] [Related]
11. The incidence and relative risk of PD-1/PD-L1 inhibitors-related colitis in non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Lin LL; Lin GF; Luo Q; Chen XQ
Int Immunopharmacol; 2019 Dec; 77():105975. PubMed ID: 31704288
[TBL] [Abstract][Full Text] [Related]
12. Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer.
Liu J; Nicum S; Reichardt P; Croitoru K; Illek B; Schmidinger M; Rogers C; Whalen C; Jayson GC
Gynecol Oncol; 2018 Jul; 150(1):173-179. PubMed ID: 29627080
[TBL] [Abstract][Full Text] [Related]
13. Practical recommendation for rash and diarrhea management in Indian patients treated with tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Parikh P; Prabhash K; Naik R; Vaid AK; Goswami C; Rajappa S; Noronha V; Joshi A; Chacko RT; Aggarwal S; Doval DC
Indian J Cancer; 2016; 53(1):87-91. PubMed ID: 27146751
[TBL] [Abstract][Full Text] [Related]
14. Diarrhea With HER2-Targeted Agents in Cancer Patients: A Systematic Review and Meta-Analysis.
Li J
J Clin Pharmacol; 2019 Jul; 59(7):935-946. PubMed ID: 30707455
[TBL] [Abstract][Full Text] [Related]
15. Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population.
Turck D; Bernet JP; Marx J; Kempf H; Giard P; Walbaum O; Lacombe A; Rembert F; Toursel F; Bernasconi P; Gottrand F; McFarland LV; Bloch K
J Pediatr Gastroenterol Nutr; 2003 Jul; 37(1):22-6. PubMed ID: 12827001
[TBL] [Abstract][Full Text] [Related]
16. Medication guide for the perioperative management of oral antineoplastic agents in cancer patients.
Villanueva-Bueno C; Escudero-Vilaplana V; Collado-Borrell R; Giménez-Manzorro Á; Ribed A; Marzal-Alfaro B; Revuelta-Herrero JL; Gonzalez-Haba E; Herranz A; Sanjurjo M
Expert Opin Drug Saf; 2022 Jan; 21(1):107-119. PubMed ID: 34357828
[TBL] [Abstract][Full Text] [Related]
17. The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea.
Rugo HS; Di Palma JA; Tripathy D; Bryce R; Moran S; Olek E; Bosserman L
Breast Cancer Res Treat; 2019 May; 175(1):5-15. PubMed ID: 30671765
[TBL] [Abstract][Full Text] [Related]
18. Substantial reduction in severe diarrheal morbidity by daily zinc supplementation in young north Indian children.
Bhandari N; Bahl R; Taneja S; Strand T; Mølbak K; Ulvik RJ; Sommerfelt H; Bhan MK
Pediatrics; 2002 Jun; 109(6):e86. PubMed ID: 12042580
[TBL] [Abstract][Full Text] [Related]
19. Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Bines J; Procter M; Restuccia E; Viale G; Zardavas D; Suter T; Arahmani A; Van Dooren V; Baselga J; Clark E; Eng-Wong J; Gelber RD; Piccart M; Mobus V; de Azambuja E;
Clin Breast Cancer; 2020 Apr; 20(2):174-181.e3. PubMed ID: 31924513
[TBL] [Abstract][Full Text] [Related]
20. Oral antineoplastic agent interactions with medicinal plants and food: an issue to take into account.
Collado-Borrell R; Escudero-Vilaplana V; Romero-Jiménez R; Iglesias-Peinado I; Herranz-Alonso A; Sanjurjo-Sáez M
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2319-30. PubMed ID: 27316629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
